Axon Therapies Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $7.5M
Latest Deal Amount
  • Investors
  • 3

Axon Therapies General Information

Description

Developer of a healthcare device designed to treat neurogenic syncope and heart failure. The company's device is based on a novel neuro-modulation approach, enabling clinicians to begin treatment more quickly, resulting in a higher likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 315 West 36th Street
  • New York, NY 10018
  • United States
+1 (212) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Axon Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 07-Feb-2019 $7.5M 000.00 0000 Completed Generating Revenue
3. Early Stage VC (Series AA) 26-Jun-2017 00.00 00.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series AA) 19-Apr-2016 $2M $2M 000 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Axon Therapies’s complete valuation and funding history, request access »

Axon Therapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A V 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.00
Series A NV 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series AA NV 1,833,334 $0.001000 $0.11 $1.8 $1.8 1x $1.8 0%
Series AA V 1,650,000 $0.001000 $0.12 $2 $2 1x $2 13.55%
To view Axon Therapies’s complete cap table history, request access »

Axon Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a healthcare device designed to treat neurogenic syncope and heart failure. The company's device is based o
Therapeutic Devices
New York, NY
12 As of 2021
000.00
000 0000-00-00
00000000000 000.00

0000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
00000000000 0000000
Minneapolis, MN
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000 00

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
00000000000 0000000
Newtown, PA
0 As of 0000
000.00
000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Axon Therapies Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CVRx Formerly VC-backed Minneapolis, MN 00 00000 00000000 00000
00000 000000000000 Venture Capital-Backed Newtown, PA 0 000.00 00000000000 000.00
000000 Angel-Backed Eagan, MN 0000 000000000 - 0000
000000 00000 Venture Capital-Backed Santa Clara, CA 00 00000 00000000000 00000
000000000 Corporation Irvine, CA 000 0000 0000000000.
You’re viewing 5 of 23 competitors. Get the full list »

Axon Therapies Patents

Axon Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3089217-A1 Methods and devices for endovascular ablation of a splanchnic nerve Pending 26-Jan-2018 00000000000
AU-2019210741-A1 Methods and devices for endovascular ablation of a splanchnic nerve Pending 26-Jan-2018 00000000000
US-20210128229-A1 Methods and devices for endovascular ablation of a splanchnic nerve Pending 26-Jan-2018 00000000000
EP-3743147-A1 Methods and devices for endovascular ablation of a splanchnic nerve Pending 26-Jan-2018 00000000000
JP-2021511163-A Methods and devices for intravascular ablation of the splanchnic nerve Pending 26-Jan-2018 A61B18/1492

Axon Therapies Executive Team (3)

Name Title Board Seat Contact Info
Chad Hoskins Chief Executive Officer
Howard Levin MD Co-Founder, President & Board Member
Mark Gelfand Co-Founder & Board Member
To view Axon Therapies’s complete executive team members history, request access »

Axon Therapies Board Members (8)

Name Representing Role Since
Andrew ElBardissi MD Deerfield Management Board Member 000 0000
Howard Levin MD Self Co-Founder, President & Board Member 000 0000
Imran Eba Action Potential Venture Capital Board Member 000 0000
Mark Gelfand Self Co-Founder & Board Member 000 0000
Mitchell Bloom JD Goodwin Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Axon Therapies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axon Therapies Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Deerfield Management Venture Capital Minority 000 0000 000000 0
Action Potential Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
Coridea VC-Backed Company 000 0000 000000 0
To view Axon Therapies’s complete investors history, request access »